Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,414 across all filing types
Latest filing 2025-06-02 M&A Activity
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Communiqué de presse : Sanofi acquiert Blueprint Medicines, enrichit son portefeuille dans les maladies immunologiques rares et ajoute un pipeline d’immunologie de stade précoce
M&A Activity Classification · 98% confidence The document is a press release ("Communiqué de presse") announcing a major corporate action: Sanofi's acquisition of Blueprint Medicines. It details the terms of the transaction (cash payment, CVRs, total value of $9.1B to $9.5B), the strategic rationale (enriching the immunology and rare disease portfolios), and includes quotes from the CEOs of both companies. This type of announcement, detailing a merger or takeover proposal, directly corresponds to the definition of M&A Activity (TAR). It is not a standard periodic financial report (10-K, IR, ER) or a simple announcement of a report (RPA).
2025-06-02 French
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
M&A Activity Classification · 100% confidence The document is a formal press release announcing a definitive agreement for Sanofi to acquire Blueprint Medicines Corporation for approximately $9.1 billion. It details the transaction terms, financial considerations, strategic rationale, and includes quotes from the CEOs of both companies. This falls squarely under the definition of M&A activity (merger proposals or takeover bids).
2025-06-02 English
SC TO-C Filing
Merger & Acquisition Classification · 100% confidence The document is a Schedule TO filing with the SEC, which is a Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934. It relates to a third-party tender offer involving Sanofi and Blueprint Medicines Corporation. The document includes details about the tender offer, filing fee information, and a joint press release exhibit. This type of filing is specifically related to merger and acquisition activity, particularly tender offers. Therefore, the appropriate classification is 'Merger & Acquisition' (MA). The document length is 2413 characters, which is consistent with a detailed regulatory filing rather than a brief announcement or certification.
2025-06-02 English
SC TO-C Filing
Regulatory Filings Classification · 95% confidence The document is a Schedule TO filing with the SEC related to a tender offer under the Securities Exchange Act of 1934. It includes preliminary communications before the commencement of a tender offer for Blueprint Medicines Corporation by Sanofi and its acquisition subsidiary. The document references various exhibits including employee portal posts, social media posts, a slide deck from an investor relations call, and a call transcript. It explicitly states it is a preliminary communication and not the tender offer materials themselves, which will be filed later. The document is a regulatory filing related to M&A activity but is not itself a merger proxy statement or tender offer document. It is a Schedule TO filing, which is a regulatory filing category. Given the nature and content, the best classification is Regulatory Filings (RNS).
2025-06-02 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC under the Securities Exchange Act of 1934. It includes references to press releases about acquisitions and clinical study results, but does not contain detailed financial statements or comprehensive reports. The document length is short (1573 characters), and it primarily serves as a regulatory filing to disclose recent material events. According to the rules, Form 6-K filings are best classified under Regulatory Filings (RNS) as they are miscellaneous regulatory announcements that do not fit into other specific categories like Annual Report or Earnings Release.
2025-05-30 English
Press Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies
Earnings Release Classification · 99% confidence The document is explicitly titled '# **Press Release**' and details the results of Phase 3 clinical studies (AERIFY-1 and AERIFY-2) for a drug called itepekimab, including statistical outcomes, safety profiles, and future plans to discuss data with regulatory authorities. This format—a concise announcement of material, time-sensitive information (clinical trial results)—is characteristic of an Earnings Release (ER) or a general press release announcing significant corporate/R&D news. Since it focuses purely on the results announcement rather than being a comprehensive periodic report (like 10-K or IR), 'ER' (Earnings Release) is the most appropriate classification, as R&D updates often accompany or substitute for traditional earnings releases in biotech/pharma contexts, or it falls under the general 'Press Release' umbrella which aligns best with ER or RNS. Given the focus on specific, material results, ER is stronger than the general RNS fallback. It is not a transcript (CT), a full annual report (10-K), or a presentation (IP). Q2 2025
2025-05-30 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.